Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Proto Oncogene Tyrosine Protein Kise ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kise c Ros Oncogene 1 or c Ros Receptor Tyrosine Kise or ROS1 or EC 2.7.10.1) - Overview
Proto Oncogene Tyrosine Protein Kise ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kise c Ros Oncogene 1 or c Ros Receptor Tyrosine Kise or ROS1 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Proto Oncogene Tyrosine Protein Kise ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kise c Ros Oncogene 1 or c Ros Receptor Tyrosine Kise or ROS1 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proto Oncogene Tyrosine Protein Kise ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kise c Ros Oncogene 1 or c Ros Receptor Tyrosine Kise or ROS1 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
AnHeart Therapeutics Inc
Ascentage Pharma Group Intertiol
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Pfizer Inc
Turning Point Therapeutics Inc
Xcovery Holding Company LLC
Proto Oncogene Tyrosine Protein Kise ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kise c Ros Oncogene 1 or c Ros Receptor Tyrosine Kise or ROS1 or EC 2.7.10.1) - Drug Profiles
APG-2449 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crizotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-6051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ensartinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lorlatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
merestinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
repotrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WY-135 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proto Oncogene Tyrosine Protein Kise ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kise c Ros Oncogene 1 or c Ros Receptor Tyrosine Kise or ROS1 or EC 2.7.10.1) - Dormant Products
Proto Oncogene Tyrosine Protein Kise ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kise c Ros Oncogene 1 or c Ros Receptor Tyrosine Kise or ROS1 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Feb 21, 2020: Chugai obtains approval for additiol indication of Rozlytrek for ROS1 fusion-positive Non-Small Cell Lung Cancer
Jan 15, 2020: Crizotinib in NSCLC with a MET exon 14 alteration
Dec 26, 2019: Chugai obtains approval for expanded use of FoundationOne CDx Cancer Genomic Profile as a companion diagnostic of Rozlytrek for ROS1-positive Lung Cancer
Dec 13, 2019: Lancet Oncology: Entrectinib effective, well-tolerated against ROS1 and NTRK lung cancers, especially with brain metastases
Nov 12, 2019: Turning Point Therapeutics initiates phase 1/2 clinical study of Repotrectinib in pediatric patients
Nov 08, 2019: Crizotinib in c-MET- or ROS1-positive Non-Small Cell Lung Cancer
Oct 30, 2019: European Society for Medical Oncology: Phase I/II study results with Lorlatinib in ROS1-positive advanced NSCLC
Oct 29, 2019: Vanderbilt Oncologists publish results of first study to demonstrate clinical utility of resolution liquid biopsy assay to monitor response and resistance to Ensartinib
Oct 17, 2019: The Lancet Respiratory Medicine published study shows Ensartinib holds promise as a new treatment option for ALK-positive Non-Small Cell Lung Cancer (NSCLC)
Sep 25, 2019: Preclincal results of Baoyuan’s next-generation ROS1/NTRK inhibitor AB-106 published in ture Communications
Sep 06, 2019: Chugai files for expanded use of FoundationOne CDx Cancer Genomic Profile as a companion diagnostic of Rozlytrek for ROS1-positive NSCLC
Sep 04, 2019: Chugai launches Rozlytrek, an Anticancer Agent for the treatment of NTRK Fusion-Positive Solid Tumors
Sep 03, 2019: Turning Point Therapeutics announces updated interim clinical data of Repotrectinib
Aug 21, 2019: ROZLYTREK (entrectinib), FDA approved for hard-to-treat NTRK fusion-positive tumors, available at Biologics by McKesson
Aug 16, 2019: FDA approves Roche Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AnHeart Therapeutics Inc, H1 2020
Pipeline by Ascentage Pharma Group International, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Turning Point Therapeutics Inc, H1 2020
Pipeline by Xcovery Holding Company LLC, H1 2020
Dormant Projects, H1 2020